Brainstorm Cell Therapeutics Profit Margin

As of the most recent data (March 2026), BCLI shows a profit margin of 1736.44%. That compares with -3037.26% in the prior-year period — up 157.2% year over year. That is above the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCLI's profit margin is now 1736.44% (was -3037.26%) — a 157.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Brainstorm Cell Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. Brainstorm Cell Therapeutics is at 1736.44%, which is higher that average. That is roughly 12005.0% above the sector mean. Use the comparison chart on this page to see how BCLI stacks up against individual peers as well.

That compares with -3037.26% in the prior-year period — up 157.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Brainstorm Cell Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Brainstorm Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 1736.44%) with ownership activity and broader fundamentals.